Clinical trials

The following list shows the clinical trials currently open at the two sarcoma centres in London and the South East: University College London (UCLH) and The Royal Marsden (RMH). For further information please contact the research nurses at each site:

Last updated October 2020

Name Description Type Centre Age
AFATINIB FOR CHORDOMA A phase II, single arm, multi-centre trial evaluating the efficacy of Afatinib as first-line or later-line treatment in metastatic or unresectable chordoma Phase II UCLH ≥18 years
APPLE Phase I: Avelumab and hyPofractionated PalLiatve radiotherapy in metastatic soft-tissuE sarcoma Phase I RMH
Deciphera DCC-2618 A multicenter phase I, open-label study of DCC-2618 to assess safety, tolerability, efficacy, and pharmacokinetics in patients with advanced malignancies Phase I RMH
DeFI Study A randomized, double-blind, placebo-controlled, phase III trial of Nirogacestat versus placebo in adult patients with progressing desmoid tumours/aggressive fibromatosis Phase III UCLH ≥18 years
E7389-G000-213 (BOLD) A phase I/II single-arm study evaluating the safety and efficacy of Eribulin Mesilate in combination with Irinotecan in children with refractory or recurrent solid tumours Phase I/II UCLH ≥12 months ≤18y
E7080-G000-230 (OLIE) A multicenter, open-label, randomized phase II Study to compare the efficacy and safety of Lenvatinib in combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in children, adolescents and young adults with relapsed or refractory Osteosarcoma Phase II UCLH 2 years to ≤25 years
ESPRIT ESP1/SARC025 Global Collaboration: A phase I study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma. Phase I UCLH CRF ≥ 13 years
EZH2 A phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma and Epitheliod type. Phase II RMH ≥18 years
GEMMK A phase I study to assess the safety and tolerability of pembrolizumab in combination with fixed rate gemcitabine chemotherapy in patients with leiomyosarcoma and undifferentiated pleomorphic sarcoma Phase I RMH ≥18 years
GSK 3377794 Open-label phase IIb/IIa clinical trial to assess the safety, tolerability and antitumor activity of genetically engineered NY-ESO-1 specific (c259) T Cells (GSK3377794) in Combination with anti-cancer agents including Pembrolizumab in HLA-A2+ participants with NY-ESO-1 and/or LAGE-1a positive relapsed and refractory Synovial Sarcoma Phase Ib/IIa UCLH ≥10 y
HGUS-EORTC 62113 A randomized double-blind phase II study evaluating the role of maintenance cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) or response to doxorubicin +/- ifosfamide or in metastatic first line treatment. Phase II RMH
UCLH
≥18 years
ICONIC Improving outcomes through collaboration in osteosarcoma UCLH
IMRIS A phase II study of intensity modulated radiotherapy (IMRT) in primary bone (STS cohort closed) Phase II UCLH ≥16 years
Intrigue A phase III, interventional, randomized, multicenter, open-label study of DCC-2618 vs sunitinib in patients with advanced gastrointestinal stromal tumors after failure of Imatinib Phase III RMH,UCLH ≥18 years
JVO2 A Randomized, Open-Label Phase II Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Synovial Sarcoma Phase II RMH
KCP-330-020 (SEAL) A phase II/III multicentre, randomised, double-blind study of Selinexor (KPT - 330) verus placebo in patient with advanced unresectable differentiated liposarcoma Phase II/III UCLH ≥12 years
KINDRED The International Sarcoma Kindred Study: a global multi‐site prospective cancer genetics study. Translational RMH
UCLH
≥15 years
KX-ORAX-010 A Pilot Study of Oraxol in Subjects with Cutaneous Angiosarcoma RMH
PROSPECTUS PROgnoStic and PrEdiCTive ImmUnoprofiling of Sarcomas (PROSPECTUS) Retrospective TR study RMH
QUEST QUEST: QUality of life and Experiences of Sarcoma Trajectories QoL study RMH
RAPPER Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy. Translational UCLH ≥18 years
REDUCE (EORTC 1762) Reduced dose-density of denosumab for maintenance therapy of unresectable giant cell tumour of bone: a multicenter phase II study Phase II UCLH ≥18 years
rEECur International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory ewing sarcoma. Phase II/III RMH
UCLH
>4 years and < 50 years
SSG XXII A phase III prospective, multi-centre, open-label, 2 arm study for evaluation of 2 durations of adjuvant treatment with the tyrosine kinase inhibitor imastinib mesylate of operable gastrointestinal stromal cells tumour (GIST) with a high risk for recurrence. Phase III RMH
UCLH
≥18 years
SMPaeds Stratified medicine paediatrics: genomic characterisation of relapsed paediatric cancers for diagnostics and stratified therapy UCLH Paediatric tumours only
SPEARHEAD 1 A phase II single arm open-label clinical trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Phase II UCLH ≥16 and <75 years